We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) as monotherapy for treating limited-stage small cell lung cancer (LS-SCLC) in adult patients whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
The latest approval for Imfinzi in the European Union (EU) was based on data from the phase III ADRIATIC study.
Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of death by 27% as compared to placebo. Additionally, treatment with Imfinzi reduced the risk of disease progression or death by 24% versus placebo.
The approval in the EU was expected as the Committee for Medicinal Products for Human Use recommended approval of Imfinzi as monotherapy for treating LS-SCLC in adult patients whose disease has not progressed following platinum-based CRT in February 2025.
The FDA approved Imfinzi for a similar indication in December 2024.
In the past year, shares of AstraZeneca have rallied 17.8% against the industry’s decline of 7.3%.
Image Source: Zacks Investment Research
Imfinzi: A Key Revenue Driver for AZN
Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy. The drug is also approved for extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer, and endometrial cancer that is mismatch repair deficient and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries.
Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $4.72 billion in 2024. Sales rose 21% year over year at constant exchange rates, driven by demand growth across all approved indications.
Imfinzi is being evaluated for multiple cancers, either alone or in combination with other regimens, including phase III studies in earlier settings in NSCLC, bladder cancer, breast cancer, several gastrointestinal and gynecologic cancers and other solid tumors.
AZN's Phase III CALYPSO Study on Eneboparatide Meets Primary Goal
In a separate press release, AstraZeneca announced that the phase III CALYPSO study evaluating its pipeline candidate, eneboparatide for treating chronic hypoparathyroidism in adults has met its primary endpoint of normalizing serum calcium levels in the given patient population.
Data from the CALYPSO study showed that treatment with eneboparatide, an investigational PTH receptor 1 agonist, led to statistical significance in adults with chronic hypoparathyroidism versus placebo at 24 weeks.
Hypoparathyroidism patients suffer from a deficiency in parathyroid hormone production, which often leads to serious debilitating diseases. Management stated that hypoparathyroidism is one of the largest known rare diseases that affect approximately more than 200,000 people in the United States and in the EU, most of whom are women.
AstraZeneca added eneboparatide to its rare disease pipeline following the acquisition of Amolyt Pharma last year.
AZN's Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #4 (Sell).
In the past 60 days, estimates for Dynavax’s earnings per share have increased from 29 cents to 33 cents for 2025. During the same time, earnings per share have increased from 48 cents to 57 cents for 2026. In the past year, shares of DVAX have rallied 18.5%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 60 days, estimates for Arvinas’ loss per share have narrowed from $4.42 to $3.75 for 2025. During the same time, loss per share has narrowed from $4.19 to $3.65 for 2026. In the past year, shares of ARVN have plunged 80.2%.
ARVN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.56%.
In the past 60 days, estimates for BioMarin’s earnings per share have increased from $4.01 to $4.31 for 2025. During the same time, earnings per share have increased from $5.17 to $5.35 for 2026. In the past year, shares of BMRN have declined 17.1%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
AstraZeneca (AZN - Free Report) recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) as monotherapy for treating limited-stage small cell lung cancer (LS-SCLC) in adult patients whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
The latest approval for Imfinzi in the European Union (EU) was based on data from the phase III ADRIATIC study.
Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of death by 27% as compared to placebo. Additionally, treatment with Imfinzi reduced the risk of disease progression or death by 24% versus placebo.
The approval in the EU was expected as the Committee for Medicinal Products for Human Use recommended approval of Imfinzi as monotherapy for treating LS-SCLC in adult patients whose disease has not progressed following platinum-based CRT in February 2025.
The FDA approved Imfinzi for a similar indication in December 2024.
In the past year, shares of AstraZeneca have rallied 17.8% against the industry’s decline of 7.3%.
Image Source: Zacks Investment Research
Imfinzi: A Key Revenue Driver for AZN
Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy. The drug is also approved for extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer, and endometrial cancer that is mismatch repair deficient and in combination with Imjudo in unresectable hepatocellular carcinoma in some countries.
Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $4.72 billion in 2024. Sales rose 21% year over year at constant exchange rates, driven by demand growth across all approved indications.
Imfinzi is being evaluated for multiple cancers, either alone or in combination with other regimens, including phase III studies in earlier settings in NSCLC, bladder cancer, breast cancer, several gastrointestinal and gynecologic cancers and other solid tumors.
AZN's Phase III CALYPSO Study on Eneboparatide Meets Primary Goal
In a separate press release, AstraZeneca announced that the phase III CALYPSO study evaluating its pipeline candidate, eneboparatide for treating chronic hypoparathyroidism in adults has met its primary endpoint of normalizing serum calcium levels in the given patient population.
Data from the CALYPSO study showed that treatment with eneboparatide, an investigational PTH receptor 1 agonist, led to statistical significance in adults with chronic hypoparathyroidism versus placebo at 24 weeks.
Hypoparathyroidism patients suffer from a deficiency in parathyroid hormone production, which often leads to serious debilitating diseases. Management stated that hypoparathyroidism is one of the largest known rare diseases that affect approximately more than 200,000 people in the United States and in the EU, most of whom are women.
AstraZeneca added eneboparatide to its rare disease pipeline following the acquisition of Amolyt Pharma last year.
AZN's Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Dynavax Technologies Corporation (DVAX - Free Report) , Arvinas Inc (ARVN - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Dynavax’s earnings per share have increased from 29 cents to 33 cents for 2025. During the same time, earnings per share have increased from 48 cents to 57 cents for 2026. In the past year, shares of DVAX have rallied 18.5%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 60 days, estimates for Arvinas’ loss per share have narrowed from $4.42 to $3.75 for 2025. During the same time, loss per share has narrowed from $4.19 to $3.65 for 2026. In the past year, shares of ARVN have plunged 80.2%.
ARVN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.56%.
In the past 60 days, estimates for BioMarin’s earnings per share have increased from $4.01 to $4.31 for 2025. During the same time, earnings per share have increased from $5.17 to $5.35 for 2026. In the past year, shares of BMRN have declined 17.1%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 32.36%.